Webcast scheduled for Monday, April 8 at 10:00
a.m. Eastern Time
CARLSBAD, Calif., March 28,
2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.
(NASDAQ: IONS) announced today that it will host a live webcast on
Monday, April 8th at
10:00 a.m. Eastern Time to discuss
the olezarsen Phase 3 Balance study results in patients with
familial chylomicronemia syndrome (FCS) presented at the 2024
American College of Cardiology Annual Meeting.
The webcast may be accessed at
https://ir.ionispharma.com/events-and-presentations/upcoming-events.
A replay will be available for a limited time at the same
address.
About Ionis Pharmaceuticals, Inc.
For three decades,
Ionis has invented medicines that bring better futures to people
with serious diseases. Ionis currently has five marketed medicines
and a leading pipeline in neurology, cardiology, and other areas of
high patient need. As the pioneer in RNA-targeted medicines, Ionis
continues to drive innovation in RNA therapies in addition to
advancing new approaches in gene editing. A deep understanding of
disease biology and industry-leading technology propels our work,
coupled with a passion and urgency to deliver life-changing
advances for patients. To learn more about Ionis, visit
Ionispharma.com and follow us on X (Twitter) and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ionis-to-hold-olezarsen-phase-3-data-webcast-302101842.html
SOURCE Ionis Pharmaceuticals, Inc.